We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`

By LabMedica International staff writers
Posted on 26 Oct 2022
Image: The new saliva-based PCR test kit can also be carried in the company`s COVID-19 vending machines (Photo courtesy of Shield T3)
Image: The new saliva-based PCR test kit can also be carried in the company`s COVID-19 vending machines (Photo courtesy of Shield T3)

With few travel restrictions in place and socializing back to normal, the annual winter rise in COVID-19 cases is "poised to collide with a resurgent influenza season, causing a 'twindemic' - or even a 'tripledemic,' with a third pathogen, respiratory syncytial virus, or R.S.V., in the mix. The three viruses have similar symptoms - fever, cough and congestion - but very different treatment methods, making quick identification important. Now, a new saliva-based PCR test kit can screen for the three illnesses - COVID-19, Influenza A/B and respiratory syncytial virus, or RSV – to meet the challenges of a potential "tripledemic" this winter.

The new test launched by Shield T3 (Champaign-Urbana, IL, USA), a spinout of the University of Illinois System's Discovery Partners Institute (Chicago, IL, USA), will help customers know within 24 hours if they have one of these three viruses. The Shield T3 kit, which is no bigger than a wallet, requires users to provide a small sample of drool and then mail the kit back to one of the company's CLIA-certified labs. Lab technicians run two separate tests on the sample, one for COVID, and one for flu and R.S.V.

The test kit is currently available to Shield T3 partners, including schools and companies, and also can be carried in the company's new COVID-19 vending machines, which are stocked with tests. The cost of the test is USD 70 or less, which represents significant savings over running the tests in a clinical setting. School administrators are able to access demand and positivity-rate data from the tests via an online dashboard.

"This is so much easier and less expensive than going to a campus clinic or a doctor," said David Clark, Shield T3's CEO. "We're working to become your partner for easy, rapid and accurate diagnostic tests from home, which is where you want to be if you're sick."

"Given the current state of the pandemic, when you're sick these days, you have no idea what you have; it could just be a cold, but it could be something, like COVID, that requires you to isolate," said Bill Jackson, Shield T3's principal officer. "This test gives our customers a quicker answer."

Related Links:
Shield T3
Discovery Partners Institute

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Collection and Transport System
PurSafe Plus®
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
New
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Molecular Diagnostics

view channel
Image: Left is the original cell image and right is same cell image zoomed in and rendered in the special imaging software (Photo courtesy of FIU)

Brain Inflammation Biomarker Detects Alzheimer’s Years Before Symptoms Appear

Alzheimer’s disease affects millions globally, but patients are often diagnosed only after memory loss and other symptoms appear, when brain damage is already extensive. Detecting the disease much earlier... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more